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representative drug dispensing data from ambulatory care). The statistical analy-
sis was performed using SAS Enterprise Guide 4.1. Results: The average price of 
medicines in the NHS market reduced significantly. Until March 2013, the average 
price of generics reduced 59.0% and brands 12.9%. The margins of pharmacies and 
wholesalers decreased in 2012. As a consequence, the outpatient pharmaceutical 
market decreased € 752 million and the NHS expenditure € 468.1 million, between 
2010 and 2012. However, hospital market in 2012 remains at the same level observed 
in 2010. In the first quarter of 2013, outpatient market reduced another 90.3 million 
€ and NHS expenditure € 49.7 M, of which 21% is due to the reduction of distribution 
margins. ConClusions: Even before the MoU, several changes led to a great reduc-
tion of the public expenditure in 2011. This impact worsened after the MoU, with 
direct effects on the reduction of the remuneration of pharmacies and wholesalers. 
Urgent strategies that ensure the access of patients to medicines while preserving 
the sustainability of both the NHS and the network of pharmacies are required, as 
well as policies to monitor the prescribing, dispensing and utilization of medicines 
and concrete changes in the inpatient NHS expenditure.
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objeCtives: Antimicrobial resistance is still a growing health problem which 
increases morbidity, mortality, and health costs and has been associated with inap-
propriate antibiotic use. In Iran antibiotic prescription rates are high in children and 
antibiotics are the most common medication prescribed. Teaching children about 
the different types of microbes and the increasing problems of antibiotic resistance 
with unnecessary and inappropriate use of antibiotics should not only raise aware-
ness in our future generation of antibiotic users but also in the family environment. 
This study aimed to evaluate the effectiveness of the story telling in improving 
children’s knowledge about rational antibiotic use. Methods: Junior (9–11 years) 
school classes were divided into either control or intervention groups for evaluation 
of the story telling. Students were required to complete identical knowledge ques-
tionnaires at three time points (before, immediately after and 4 weeks after teach-
ing), to assess knowledge change and retention. Teaching, using story books which 
provided by National Committee on Rational Drug Use (NCRUD), was given by junior 
school teachers. Results: A total of 164 junior students, 95 were intervention and 
69 control groups, were studied. The junior story telling demonstrated a significant 
improvement in student’s knowledge (34.5% of change) and there was no significant 
decrease in student knowledge observed after a 4 week period. ConClusions: 
Availability of information on the effectiveness of intervention for improving and 
promoting appropriate antibiotics use can facilitate implementation of strategies in 
this field. Regarding the effectiveness of storytelling, it is therefore recommended 
that decison-maker place greater emphasis on the use of such interventions.
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objeCtives: Hospital formularies are usually the gatekeepers for pharmaceutical 
drugs. Typical majority members of hospital formularies are physicians, although 
most of the time the formulary is chaired by a pharmacist. As German hospitals 
are struggling with a difficult economic environment the question arises: what 
kind of decision-making criteria are applied when pharmaceutical drugs should 
be added to the formulary list? Information regarding this topic is scarce due to 
the sensitive topic of decision-making. Only one study (Thürmann et al., 1997) is 
looking into this for Germany. Methods: a total of 588 public, private and ecclesi-
astic hospitals in Germany have been contacted to participate in an online-survey 
regarding the structure of their hospital formulary, roles of members and applied 
decision-making criteria. Results: Thirty-five of 588 hospitals (6%) have finally 
participated and filled out the complete questionnaire. Out of the 35 participants, 
29 were pharmacists (82.9%) and 6 were physicians (17.1%). 34.3% of the hospitals 
have no guidelines for their decision-making and 65.7% of the hospitals with guide-
lines have written (48.6%) or verbal (17.1%) guidelines. Out of these, 78.3% discuss 
decision-making criteria, but only 47.8% talk about the relative importance of the 
discussed decision-making criteria. Budget impact (82.6%), clinical studies (69.6%) 
and price (65.2%) are the most often mentioned decision-making criteria in the 
guidelines. ConClusions: A third of the participating hospitals do not have guide-
lines for their decision-making process and only half of the guidelines discussing 
decision-making criteria also talk about the relative importance. Hospital formular-
ies in Germany do not seem to be transparent in their decision-making process. In 
addition the top 3 decision criteria in the existing guidelines include 2 economical 
criteria which lead to the question of dominance of economical versus medical or 
other criteria. Further research needs to look at the real applied decision-making 
criteria and how much impact economical criteria have on decision-making in 
German hospital formularies.
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objeCtives: In 2011, the AMNOG law changed the price-setting procedure for drugs 
in Germany. Manufacturers are now required to submit a dossier to the Federal 
Joint Committee (GBA) for newly launched or, upon specific request, already market 
products. The GBA decides on the level of additional benefit which impacts the reim-
bursement price negotiations with German sick funds. The objectives of this study 
were thus to: 1) identify ways in which manufacturers can optimize the benefit 
developing the candidates, with investigational oncology drugs representing the 
largest proportion (53%). Orphan diseases make up the second largest group with 
over a third of publicly disclosed BT therapies. In therapeutic areas with already 
available treatment options, such as Hepatitis C Virus infections and advanced mela-
noma, there is still potential for drug candidates to gain BT designation if they can 
be shown to provide an alternative to effectively treat patients that fail to respond 
to the current standard of care. ConClusions: Our investigation has highlighted 
the FDA’s focus on finding breakthrough candidates within oncology as well as 
rare genetic or orphan diseases that do not currently have adequate treatment 
options. Additionally, candidates offering alternative options to non-responders 
have also secured a place on the list, which is likely to grow as increased interest 
and awareness is generated.
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objeCtives: From October 2013, some pharmaceutical products will be required 
to undergo a medico-economic evaluation in France. The aim of this study was to 
interview key stakeholders involved in this conceptual change in order to under-
stand how this reform will be implemented and how it will affect market access 
in France. Methods: Primary research was conducted between April and June 
2013 with stakeholders from the French National Authority for Health (HAS), the 
Economic and Public Health Evaluation Commission (CEESP), the Transparency 
Commission (TC) and relevant French ministries. Interviews lasted between 45 
and 75 minutes and focused on the methodology for medico-economic assess-
ment and its implications on the French pharmaceutical pricing and reimbursement 
(P&R) process. Results: Medico-economic evaluation in France will be based on 
cost-utility or cost-effectiveness analyses, depending on whether or not quality 
of life is an important outcome. Cost-utility analyses will rely on QALYs (quality-
adjusted life years), whereas cost-effectiveness analyses will rely on survival. The 
medico-economic assessments will inform pricing negotiations, on the one hand, 
and potentially the development of prescribing guidelines, on the other. Medicines 
will be subjected to a medico-economic assessment based on their level of innova-
tion and/or on their financial impact on the health care budget. ConClusions: 
France is formally introducing the QALY into its P&R system; however, this reform 
will come with a twist on the Anglo-Saxon approach, as there will be no associated 
ICER (incremental cost-effectiveness ratio) above which the medicine will not be 
reimbursed. While there is still some level of uncertainty with regards to the medi-
cines that will be subjected to this assessment (as stakeholders have yet to put a 
quantitative value on a “significant impact” on the health care budget), the direction 
of travel is toward greater pressure on pharmaceutical prices.
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objeCtives: In 2011, we saw the introduction of an evidence-based pricing 
approach to new branded pharmaceuticals in Germany. The process arose from the 
Act of the Reform of the Market for Medicinal Products (AMNOG) and all new drugs 
must undergo clinical benefit assessment by the Federal Joint Committee (GBA) fol-
lowed by price negotiation with the German sick fund (GKV-SV) heads depending on 
whether additional benefit has been demonstrated. A review of the final GBA assess-
ments published to date was undertaken and the aim was to evaluate the implica-
tions for manufacturers considering Germany as a launch country. Methods: The 
GBA and IQWIG websites were searched for AMNOG evaluations performed between 
January 2011 to May 2013. Where appropriate the approach taken in the GBA assess-
ment was compared with that of other HTA groups in Europe. Results: The most 
important consideration for a manufacturer is choosing the right comparator in 
their submission, the core evidence document in this process. A number of drugs 
have been compared to the wrong treatment and subsequently were found to have 
no additional benefit. Some submissions chose the appropriate comparator but 
only for certain subgroups, leading to a reduced overall benefit for the new drug. 
Like most HTA groups, the preference is for mortality, morbidity and side effects 
evidence from head-to-head trials, however GBA appear to give little considera-
tion to quality of life evidence. The review also revealed that GBA make decisions 
that are independent of other HTA bodies and sometimes reject recommendations 
of its own evidence review group, IQWIG. ConClusions: Early engagement with 
GBA to agree an appropriate comparator, patient population and clinical outcome 
measures is very important to improve chances of a positive assessment. However, 
the requirements of the GBA process should be balanced with those of other key 
markets as part of the drug’s global PRA strategy.
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objeCtives: The Memorandum of Understanding signed in May 2011, between the 
Portuguese Government and the International Authorities, increased requirements 
to reduce the public expenditure with medicines. These measures included the 
major change in margins distribution system. This study aims to: 1) describe the 
MoU measures related to medicines; 2) analyze public expenditure and impact of 
distribution margins reductions on medicines public expenditure, due to MoU and 
legislative changes in Portugal. Methods: Descriptive study with updates to the 
MoU and published legislation. Market analysis and simulations were computed 
based on the Pharmacy Sales Information System (a nationwide database with 
